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Cutaneous scarring can cause patients symptoms ranging from the psychological to physical pain. Although the process of normal
scarring is well described the ultimate cause of pathological scarring remains unknown. Similarly, exactly how early gestation
fetuses can heal scarlessly remains unsolved. These questions are crucial in the search for a preventative or curative antiscarring
agent. Such a discovery would be of enormous medical and commercial importance, not least because it may have application
in other tissues. In the clinical context the assessment of scars is becoming more sophisticated and new physical, medical and
surgical therapies are being introduced. This review aims to summarise some of the recent developments in scarring research for
non-specialists and specialists alike.
Copyright © 2009 Richard Baker et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cutaneous scarring is inevitable following damage to more
than 33.1% of the thickness of the skin either through
trauma or surgery [1]. An estimated 23 million people
in the UK have signiﬁcant scars and although most of
these are asymptomatic a proportion cause psychological
and physical morbidity whilst some are pathological [2].
Although scars are permanent there are established methods
of improving symptomatic scars medically or with surgical
revision [3]. However, the evidence base for most of
these treatments is poor and their eﬃcacies are limited
[3].
An eﬀective cutaneous antiscarring agent would have
profound beneﬁts in relation to trauma and burns but in
addition may have eﬃcacy in the prevention of postsurgical
abdominal adhesions and in the treatment of medical
ﬁbroses such as renal, pulmonary, and hepatic. This paper
aims to update doctors of all specialties on the current state
oftheartregardingbothresearchandtreatmentofcutaneous
scarring.
2. Methods
Pubmed and Medline were searched using terms “scar” and
“cutaneous” from 1998 onwards. Personal archives were also
consulted. The articles selected comprise original papers,
reviews, recommendations, and consensus reports. Whilst
some of the studies are prospective randomized controlled
trials, many are prospective or retrospective observational
reports or laboratory based studies. Although the evidence
for many antiscarring therapies is at this stage weak or in the
preclinical or development phases, much of this research is
referenced for completeness.
2.1. How Do Scars Form? A cutaneous scar is deﬁned as
dermal ﬁbrous replacement tissue and results from a wound
that has healed by resolution rather than regeneration [4].
Finalappearanceislargelyinﬂuencedbytheintervalbetween
wounding and complete healing 2 to 3 weeks later. It is here
that the doctor can do most to prevent the development of
pathological scarring. Incisions should be placed within or
parallel to the lines of Langer (wrinkle lines) (Figure 1)a n d2 Dermatology Research and Practice
Figure 1: The lines of Langer or relaxed skin tension lines.
away from anatomical sites prone to pathological scarring
such as shoulders, sternum, across joints, or near oriﬁces.
Wounds should be closed with the minimum possible
tension and paper tape applied to redistribute the tension
over a greater surface area. Infection, foreign bodies (e.g.,
retained sutures) or prolonged healing (beyond 2 weeks) will
all contribute to poorer scarring [5].
Once the scar has formed it undergoes several distinct
macro- and microscopic changes during the maturation
process and is complete on average after 1 year [6]. Patients
under 30 years exhibit a slower rate of scar maturation and
poorer ﬁnal appearance than patients over 55 years [6]. The
redness of a scar fades after 7 months and in contrast with
rubor elsewhere does not reﬂect an inﬂammatory process
(after the ﬁrst month) [7]. The scar is devoid of dermal
appendages and never reaches the same tensile strength as
the surrounding skin [8].
Scar tissue consists mainly of disorganised collagenous
extracellular matrix. This is produced by myoﬁbroblasts
(Figure 2)w h i c hd i ﬀerentiate from dermal ﬁbroblasts in
response to wounding which causes a rise in the local
concentration of transforming growth factor-β (TGF-β).
TGF-β is an important cytokine associated with ﬁbrosis
in many tissue types [8]. Myoﬁbroblasts are characterised
by contractile microﬁlaments of smooth muscle proteins
such as α-smooth muscle actin, which give scar tissue
its contracting property and together with TGF-β are the
principal targets of attempts to suppress scarring [9, 10].
2.2. How Are Scars Assessed? Histopathological examination
isthegoldstandardforscarassessmentbutisnotappropriate
for monitoring the response to therapy of scars in a clinic
settingorinthecontextofclinicaltrials,soclinicaltoolshave
been developed that facilitate objective assessment of scars.
The ﬁrst such scale, the Vancouver Burn Scar Assessment
Scale rates scars on pigmentation, vascularity, pliability, and
height [11]. This initial concept has been developed to make
descriptions numerical, to include scar location, patient
observation and to broaden application to linear nonburn
Figure 2: A human myoﬁbroblast, ×40 magniﬁcation. The nucleus
is stained orange with propidium iodide and the ﬁlaments of α-
smooth muscle actin are immunostained green.
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Figure 3: The global scar comparison scale. The photographic
records of each scar are placed side by side over a double-
ended visual analogue scale which represents percentage scar
improvement. The 0% rating equates to an assessors opinion that
there is no detectible diﬀerence between the two scars; whereas
the 100% rating on either side means that that particular scar is
so improved that it is imperceptible from the surrounding normal
skin.
scars [4, 12, 13]. To compensate for the high intrapatient
variation in scars the Global Scar Comparison Scale has been
recently designed and validated by Renovo Ltd speciﬁcally
for assessing new antiscarring therapies [14]. Images of
treated and placebo-treated scars are compared side by side
combiningarankingandvisualanalogue-scalemeasurement
in one assessment allowing detection of smaller diﬀerences
in scarring outcome (Figure 3). However, all these scales are
inevitably limited by their subjectivity so several instruments
havebeendesignedtocircumventthisproblembyobjectively
measuring certain properties of a scar. These include red-
ness/erythema (e.g., Minolta Chromameter), pigmentation
(e.g., DermaSpectometer), thickness (ultrasound), surface
areaandtexture(digitalphotographyandopticalormechan-
ical proﬁlometers), and suppleness (e.g., Cutometer) [10,
13, 15, 16]. Finally, there are experimental 3D imaging
technologies that can accurately calculate scar volume and
digitalimageanalysisisalsolikelytobecomemoreimportant
[17].Dermatology Research and Practice 3
Figure 4: A hypertrophic postsurgical scar.
2.3.WhyDoEarly-GestationFetusesNotScar? Thepossibility
of manipulating scar formation scarless healing was raised
by the observation of scarless healing of amputation stumps
causedbyamnioticbandsina20-weekoldhumanfetus[18].
Although the nonscarring fetus is generating new skin and
is bathed in amniotic ﬂuid, these conditions remain in late
gestation when the fetus does scar. However, there are three
important diﬀerences in the early gestation fetus that may
explain the diﬀerent response to wounding.
(1) Reduced Inﬂammatory Response in the Early Gestation
Fetus [19]. Fetal skin has fewer macrophages and lympho-
cytes compared to adult skin and inﬂammatory cells persist
for less time in the wound [19–21]. This maybe due to the
reduced degranulation of fetal platelets, their lower PDGF
and TGF-β1 and 2 content, or reduced aggregation [22–25].
(2) Diﬀering Growth Factor Proﬁle [19]. Levels of the proﬁ-
brotic TGF-β1a n dT G F - β2 are higher in scarring fetal rat
wounds than in non-scarring fetal wounds; whereas levels of
the antiﬁbrotic TGF-β3 are higher in non-scarring wounds
and this is repeated in human fetal skin [26, 27]. Other
cytokines are implicated such as VEGF (antiﬁbrotic), PDGF,
and FGF-2 and non-cytokines such as hydrogen peroxide
(proﬁbrotic) [15, 28, 29].
(3) Innately Diﬀerent Fibroblasts [30]. Fetal ﬁbroblasts
migrate faster, show less propensity to diﬀerentiate into
myoﬁbroblasts and respond diﬀerently to certain scarring-
associated cytokines such as insulin-like growth factors and
TGF-β1 than their adult counterparts [31–34]. Although
TGF-β1autostimulatesexpressionofitsowngeneinscarring
ﬁbroblasts, non-scarring fetal ﬁbroblasts display only a
short-lived response to TGF-β1[ 35].
2.4. What Are Pathological Scars? Hypertrophic (Figure 4)
andkeloidscars(Figure 5)arebothformsofexcessivedermal
ﬁbrosis.Theyareboth characterisedbyincreased vascularity,
high mesenchymal density, inﬂammatory cell inﬁltration,
and a thickened epidermis [36]. However, their clinical char-
acteristics and pathologies intrinsically diﬀer with keloids
Figure 5: Presternal keloid scar.
being the more complex, extreme, and challenging to treat
(see Table 1). The treatment of both of these types of scar
can be protracted and is best managed by a specialist from
the outset.
2.5. Why Do Some Scars Become Pathological? Pathological
scars are thought to be caused by disordered regulation
of wound cellularity and collagen synthesis [37]. Growth
factors, extracellular matrix components, abnormal collagen
turnover, sebum immunoreactivity, genetic inﬂuences, and
tension have all been implicated [38]. Pathological scars are
hyperresponsive to TGF-β1 with connective tissue growth
factor expression increases 150-fold and 100-fold in hyper-
trophic and keloid scars, respectively, in response to TGF-β1
compared with normal ﬁbroblasts [39]. Failure of apoptosis
mayalsohavearole,keloidﬁbroblastsinparticulararehighly
resistant to fatty acid synthase-mediated apoptosis and the
tumour suppressor genes, p53 and p63, which are involved
intheinductionofapoptosis,areupregulated[40–43].There
appear to be predisposing systemic traits too. Burn patients
who subsequently develop hypertrophic scars have higher
IL-10, TGF-β serum levels, and elevated numbers of IL-4-
positive Th 2 cells early after burn injury compared with
those that develop normal scars [44]. Familial clustering
and the markedly higher predisposition of patients of Afro-
Carribean origin to developing keloids suggest that there is
a major genetic contribution with keloid susceptibility loci
having been found on chromosomes 2q23 and 7p11 [45, 46].
2.6.WhyDoWeNeedAntiscarringTherapies? Asproblematic
scars are often caused by an intrinsic dysfunction of the
process of wound healing, surgery simply serves to recreate
the precipitating event and commonly results in recurrence.
Several physical, medical, and surgical therapies have there-
fore been developed to both prevent and treat poor scarring.
2.7. What Physical Antiscarring Therapies Exist? Silicone
gel sheeting remains ﬁrst-line treatment for normal and
hypertrophic scars and has been proved eﬃcacious in
a large metanalysis [47, 48]. The mechanism of action
remainsunclear.Pressuretherapyintheformofcompression4 Dermatology Research and Practice
Table 1: Normal, hypertrophic, and keloid scars compared.
Normal Hypertrophic Keloid
Conﬁned to edges of original wound Conﬁned to edges of original wound Extends beyond edges of wound
Gradual fading and atrophy after maturation Regresses after initial peak
(although often over several years)
Progressive
No treatment required First-line treatment: silicone patches
or gels
First-line treatment:
intralesional steroid injection
Best in the elderly Worst in the young M o r ec o m m o ni nd a r k e rs k i n
Normal response to TGF-β1 Abnormal response to TGF-β1 Failure of apoptosis
garments and hydrotherapy are widely used particularly for
hypertrophic burn scars; however strong evidence for their
eﬃcacy is lacking [3].
New lasers are emerging, such as the nonablative frac-
tional laser, for the treatment of scarring although evidence
of eﬃcacy is again largely anecdotal [49]. Pulsed-dye lasers
may be useful in treating resistant keloids in combination
with intralesional steroids [3, 50]. They may also ﬂatten
hypertrophic scars and reduce erythema although with
conﬂicting reports of success [51]. So called “laser welding”
of skin wounds seems to produce better scars in rats [52].
Cryotherapy tends to be limited to the treatment of
very small scars because of the attendant side-eﬀects of
pigmentation changes, skin atrophy, and pain. However, a
methodofdeliveringintralesionalcryotherapyusinganeedle
attached to a liquid nitrogen source has been described in
a small observational study which appears to be eﬀective at
shrinking keloid scars [53].
Radiotherapy in combination with surgery is an eﬀective
treatment of keloids but is limited in practice by the risk
of carcinogenesis [38]. Other physical therapies include
massage, ultrasound, medical tattooing/camouﬂage, static
electricity, and pulsed electrical stimulation. These are as yet
unproven by randomised controlled trials.
2.8. What Medical Antiscarring Therapies Exist? Intralesional
injection of corticosteroids, usually triamcinolone, is the
most commonly accepted medical treatment of pathological
scarring [3]. Steroids are most eﬀective in the treatment
of keloids rather than hypertrophic scars, particularly when
combined with other modalities [54]. However, steroids do
not improve normal scars and are marred by side eﬀects
such as depigmentation and telangiectasias, so many other
potential medical therapies are under investigation.
Interferon has been shown to increase collagen break-
down, improve hypertrophic scars, and prevent recurrence
of keloids better than triamcinolone [3]. However, topical
imiquimod (interferon α 2 inducer) and interferon α2b have
both recently been found to be ineﬀective in the treatment of
normal scars and keloids, respectively [55, 56].
The cytotoxic cancer chemotherapy drugs 5-ﬂuorouracil
and bleomycin have so far been used successfully to ﬂatten
hypertrophic and keloid scars in small studies [57, 58].
Other antiscarring therapies under investigation include
onion extract, AZX100 (a phosphopeptide analogue of
HSP20 [heat-shock-related protein]), pentoxifylline, prolyl-
4 hydroxylase, verapamil, tacrolimus, and anti-TNF-α agents
[59–65].
Perhaps the most promising potential medical therapy
stems from the research into fetal scarring and TGF-β.I n
particular, an improvement in scarring in rat wounds has
been shown by neutralizing TGF-β1 alone or both TGF-
β1 and 2 (with antibodies or competitive inhibition with
mannose-6-phosphate which inhibits TGF-β activation) or
alternatively by adding TGF-β3[ 26]. These ﬁndings have led
totestingofnewagentsthatarenowundergoingphaseIIand
phase III clinical trials [66, 67].
2.9. How Can We Improve Scars Surgically? Meticulous
surgical technique remains vitally important in the ﬁnal
scarring outcome. However, using tissue adhesive glue in
place of sutures demonstrates better scars in randomised
controlled trials in breast and head and neck surgery patients
[68]. Paper tape shows equivalent cosmetic outcomes in
the treatment of pediatric facial lacerations and reduces the
incidence of hypertrophic scarring caesarean section scars
when applied for 12 weeks [69, 70].
In revision surgery, the traditional methods of re-
excision and Z- or W-plasties (reorientating scars), grafts or
ﬂaps followed by adjuvant therapy, remain the mainstay of
treatment but newer techniques are now available such as
dermabrasion,chemicalpeels,andfollicularunitmicrograft-
ing [71] .O t h e ra d v a n c e sh a v ef o c u s e do nr e d u c i n gw o u n d
tension. One method avoids tension by leaving the dermal
element of the scar unexcised and closing epithelial skin
ﬂaps over the dermal scar. Thus the scar continues to take
up the tension in the dermis but any widening is eﬀectively
hidden [72]. The similar “ﬁllet ﬂap” has been described for
revising keloid scars. The skin over the keloids are raised as
ﬂaps, the keloid tissue excised, and the skin resutured thus
closing the wound without tension [73]. Alternatively a split
thicknessskingraftcanbeappliedtothewoundbed.Tension
is avoided and the graft naturally contracts over time [74].
Caution should be applied in the practise of these new
techniquesastheirevidencebaseislargelyanecdotalorbased
on small series.Dermatology Research and Practice 5
3. Conclusion
Scarring research has seen advances in scar assessment,
prevention, and revision. Many scar treatments are being
trialled. A central, although not exclusive, role of trans-
forming growth factor beta has emerged and the possible
aetiologies of pathological scars are gradually being deﬁned.
Thepractiseofsurgerypromisestobesigniﬁcantlyimproved
in near future by the advent of eﬀective antiscarring
therapies and perhaps ultimately, completely scar-less heal-
ing.
SummaryPoints
An eﬀective therapy for the prevention/treatment of cuta-
neous scarring may have application in ﬁbrosis of other
tissues.
Scarring remains a signiﬁcant adverse consequence of
surgery, trauma, and burns with current therapies having
poor eﬃcacy and evidence base.
First-line therapy of hypertrophic scars is silicone
gel/sheeting and ﬁrst-line therapy for keloids is intralesional
steroid injection.
Correct orientation of incisions parallel to the lines of
Langer,reducingwoundtensionandapplyingpapertapecan
help to prevent postoperative hypertrophic scarring.
Tips for Nonspecialists
Normal scars take a year to mature and should be ﬂat and
pale. Red, raised, or painful scars are hypertrophic or even
keloid and should be treated as such.
Symptomatic scars can be improved and patients with
troublesome scars should be referred to a plastic surgeon.
Ongoing Research
Research into fetal (nonscarring) cutaneous healing and
transforming growth factor-β are at the forefront of attempts
to design an antiscarring drug.
Manipulation of the TGF-β isoforms and related bioac-
tive molecules to inhibit scar production understanding why
some scars become pathological.
A range of medical therapies are being trialled including
cytotoxic drugs, interferon and onion extract and AZX100
(please note that this is not an exhaustive list).
Plastic surgical techniques to revise scars and treat
pathological scars.
UnansweredQuestions
Why do some tissues scar but not others?
How do steroids and silicone improve pathological scars?
How can we more accurately predict which patients may
develop pathological scars following surgery or injury?
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